Description
HGH Fragment 176-191 is a synthetic peptide that reconstructs amino acids 176-191 of human growth hormone. It belongs to the HGH fragment compound family and is closely related to AOD-9604, which covers sequence 177-191. Both address the C-terminal end of the HGH molecule, which has been associated with lipolysis properties in preclinical studies.
The research mechanism lies in fat mobilization. In animal models, HGH Frag 176-191 has been associated with increased hormone-sensitive lipase activity and enhanced beta-3 adrenoreceptor stimulation. The advantage over full HGH: the growth-promoting and insulin sensitivity modulating effects of the complete hormone are largely absent. This makes the fragment a research tool for isolated lipolysis studies.
In preclinical setups, HGH Frag 176-191 is typically used as a small peptide with short half-life. The frequent application interval (multiple times daily) is a research characteristic resulting from the rapid clearance of the fragment.
Structurally, with 16 amino acids, HGH Frag 176-191 is a substantially smaller molecule than the complete HGH (191 amino acids). This reduction in molecular complexity is part of the research hypothesis: by eliminating growth-axis activating sequences, the metabolic effect is isolated.
HGH Frag 176-191 is available in 5mg vials as 10-vial packs.
This information is for research and educational purposes only. No medical recommendations.
Risks & Safety
HGH Fragment 176-191 is considered well tolerated per study reports. Because the C-terminal fragment largely lacks the growth-promoting and insulin sensitivity modulating sequences of the full hormone, the profile is milder than that of complete HGH.
Observed in research and user reports:
- Injection site: mild redness, pressure or transient irritation at the injection site is the most common observation with subcutaneous use.
- Mild profile: because the fragment largely does not activate the growth axis, the GH-typical observations such as pronounced water retention or carpal-tunnel-type symptoms are largely absent from the literature.
- Short half-life: the small peptide is degraded quickly, requiring frequent application intervals - though the profile remains mild.
- Occasionally brief fatigue or a mild feeling of warmth shortly after application is reported.
- No long-term data: robust long-term human studies on research use do not exist. The profile rests primarily on animal models and short-term anecdotal experience.
This classification does not replace medical advice. Risk and responsibility for any actual use lie entirely with the buyer.
Studies
- Antiobesity effects of growth hormone fragment 176-191 - European Journal of Endocrinology 2005: Overview of fragment-specific metabolic effects.
- GH and the regulation of lipolysis - Best Practice & Research Clinical Endocrinology 2008: Mechanism overview of the HGH lipolysis axis.
- Pharmacology of growth hormone-derived peptides - Peptides 2014: Comparison of various HGH fragments including 176-191.
